Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Neonatal Nitric Oxide Use: Predictors of Response and Financial Implications

Journal of Perinatology volume 23, pages 128–132 (2003)Cite this article

Abstract

OBJECTIVE: To determine predictors of sustained response to inhaled nitric oxide (INO) and the financial impact of INO commercialization.

DESIGN/METHODS: We evaluated the records of extra-corporeal membrane oxygenation (ECMO)-eligible infants consecutively treated with INO. We calculated the charges for INO therapy and for ECMO for each patient so treated.

PUBLISHED BY ELSEVIER SCIENCE LTD.RESULTS: In total, 52 (59%) of 88 infants avoided ECMO; all received INO for >48 hours; all survived. A total of 36 infants received ECMO; 21 infants after <24 hours of INO; seven infants after 24 to 48 hours; and eight infants >48 hours of INO; one infant died. In total, 51 infants had sustained responses to INO; 19 infants were nonresponders and 18 were transient responders. Infants with PPHN and those older than 24 hours were more likely to respond to INO. Total INO charges for all 88 infants were $1,048,000. Total ECMO charges for the 36 infants so treated were $1,710,000.

CONCLUSIONS: INO has added a charge-saving therapy to selective infants who can avoid ECMO.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997;336(9):597–604.

  2. Roberts JD, Fineman JR, Morin III FC, et al. For the Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 1997;336(9):605–610.

    Article  CAS  PubMed  Google Scholar 

  3. Davidson D, Barefield ES, Kattwinkel J, et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose–response, multicenter study. Pediatrics 1998;101(3):325–334.

    Article  CAS  PubMed  Google Scholar 

  4. Clark RH, Kueser TJ, Walker MW, et al. For the Clinical Inhaled Nitric Oxide Research Group. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med 2000;342(7):469–474.

    Article  CAS  PubMed  Google Scholar 

  5. Day RW, Lynch JM, White KS, Ward RM . Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension. Pediatrics 1996;98(4):698–705.

    CAS  PubMed  Google Scholar 

  6. Truog WE . Inhaled nitric oxide: A tenth anniversary observation. Pediatrics 1998;101:696–697.

    Article  CAS  PubMed  Google Scholar 

  7. Goldman AP, Tasker RC, Haworth SG, Sigston PE, Macrae DJ . Four patterns of response to inhaled nitric oxide for persistent pulmonary hypertension of the newborn. Pediatrics 1996;98(4):706–713.

    CAS  PubMed  Google Scholar 

  8. George TN, Johnson KJ, Bates JN, Segar JL . The effect of inhaled nitric oxide therapy on bleeding time and platelet aggregation in neonates. J Pediatr 1998;132:731–734.

    Article  CAS  PubMed  Google Scholar 

  9. Kobayashi T, Gabazza EC, Shimizu S, et al. Long-term inhalation of high-dose nitric oxide increases intraalveolar activation of coagulation system in mice. Am J Respir Crit Care Med 2001;163:1676–1682.

    Article  CAS  PubMed  Google Scholar 

  10. Hallman M, Bry K, Turbow R, Waffarn F, Lappalainen U . Pulmonary toxicity associated with nitric oxide in term infants with severe respiratory failure. J Pediatr 1998;132(5):827–829.

    Article  CAS  PubMed  Google Scholar 

  11. Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. Pediatrics 1997;99(6):838–845.

  12. Kinsella JP, Truog WE, Walsh WF, et al. Randomized multicenter trial of inhaled nitric oxide and high frequency oscillatory ventilation in severe persistent pulmonary hypertension of the newborn. J Pediatr 1997;131:55–62.

    Article  CAS  PubMed  Google Scholar 

  13. Zhou H, Gao Y, Raj JU . Antenatal betamethasone therapy augments nitric oxide-mediated relaxation of preterm ovine pulmonary veins. Am Physiol Soc 1996;390–396.

    Article  CAS  PubMed  Google Scholar 

  14. Pearson DL, Dawling S, Walsh WF, et al. Neonatal pulmonary hypertension. Urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. N Engl J Med 2001;344(24):1832–1838.

    Article  CAS  PubMed  Google Scholar 

  15. Christenson J, Lavoie A, O'Connor M, Bhorade S, Pohlman A, Hall JB . The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide. Am J Respir Crit Care Med 2000;161: 1443–1449.

    Article  CAS  PubMed  Google Scholar 

  16. Kinsella JP, Abman SH . Clinical approach to inhaled nitric oxide therapy in the newborn with hypoxemia. J Pediatr 2000;136(6):717–726.

    CAS  PubMed  Google Scholar 

  17. Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000;105(1):14–20.

    Article  CAS  PubMed  Google Scholar 

  18. Kinsella JP, Torielli F, Ziegler JW, Ivy DD, Abman SH . Dipyridamole augmentation of response to NO. Lancet 1995;346:647–648.

    Article  CAS  PubMed  Google Scholar 

  19. Thusu KG, Morin FC, Russell JA, Steinhorn RH . The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of NO. Am J Respir Crit Care Med 1995;152:1605–1610.

    Article  CAS  PubMed  Google Scholar 

  20. Truog WE, Norberg M, Thibeault DW . Effect of inhaled nitric oxide in endothelin-1-induced pulmonary hypertension. Biol Neonate 1998;73: 246–253.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Section of Neonatology, Children's Mercy Hospitals and Clinics, University of Missouri — Kansas City School of Medicine, Kansas City, MO, USA

    William E Truog MD, Cheri A Castor RN, BSN & Mark J Sheffield MD

Authors
  1. William E Truog MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cheri A Castor RN, BSN
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark J Sheffield MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported in part by R-01-HL62514 (WET).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Truog, W., Castor, C. & Sheffield, M. Neonatal Nitric Oxide Use: Predictors of Response and Financial Implications. J Perinatol 23, 128–132 (2003). https://doi.org/10.1038/sj.jp.7210864

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jp.7210864

This article is cited by

Search

Advanced search

Quick links